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Abstract: Pheochromocytomas and paragangliomas (PPGL) are rare neuroendocrine tumors that
show the highest heritability of all human neoplasms and represent a paradoxical example of genetic
heterogeneity. Amongst the elevated number of genes involved in the hereditary predisposition to
the disease (at least nineteen) there are eleven tricarboxylic acid (TCA) cycle-related genes, some of
which are also involved in the development of congenital recessive neurological disorders and other
cancers such as cutaneous and uterine leiomyomas, gastrointestinal tumors and renal cancer. Somatic
or germline mutation of genes encoding enzymes catalyzing pivotal steps of the TCA cycle not only
disrupts cellular respiration, but also causes severe alterations in mitochondrial metabolite pools.
These latter alterations lead to aberrant accumulation of “oncometabolites” that, in the end, may lead
to deregulation of the metabolic adaptation of cells to hypoxia, inhibition of the DNA repair processes
and overall pathological changes in gene expression. In this review, we will address the TCA cycle
mutations leading to the development of PPGL, and we will discuss the relevance of these mutations
for the transformation of neural crest-derived cells and potential therapeutic approaches based on the
emerging knowledge of underlying molecular alterations.
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1. Metabolism and Cancer
Almost a century ago, Nobel Prize winner Otto Warburg described how cancer cells can reprogram
glucose metabolism by dramatically increasing the rate of glucose uptake, which is fermented to
produce lactate even in the presence of oxygen and fully functioning mitochondria [1]. This observation
suggested that defects in mitochondrial respiration could be the underlying cause of cancer. Although
this aerobic glycolytic mechanism, known as the Warburg effect, has been studied extensively, its
benefits for cell growth and survival are not well understood. In fact, nowadays it is more accepted
that genetic events occurring in cancer cells are the cause of the alterations in metabolism observed by
Warburg in the 1920s. At the beginning of the 21st century, the first mutations in the SDHD gene were
reported, providing for the first time a link between germline alterations in a metabolic gene and the
development of cancer, and demonstrating how disruption of mitochondrial respiration may lead to
tumor development [2]. Moreover, the description of the first germline mutations in the SDHD gene in
patients with hereditary pheochromocytoma (PCC) and paraganglioma (PGL) (together referred to as
PPGL) marked a milestone in the study of this rare disease.
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2. Germline or Somatic Disruption of the Tricarboxylic Acid (TCA) Cycle Leads to PPGL
Development
For a long time it was thought that the tricarboxylic acid (TCA) cycle was so crucial to the
metabolism of living cells that any significant defect, including mutations affecting the pivotal
enzymatic activities, would be highly unlikely and probably incompatible with life. To date, thirteen
TCA cycle-related genes have been described to be involved in the development of different cancers such
as cutaneous and uterine leiomyomas, gastrointestinal tumors, gliomas, renal cancer, and especially
PPGL. Thus, ~23% of PPGLs are found carrying mutations in genes encoding energy metabolism
enzymes such as the succinate dehydrogenase (SDH) subunits (SDHx genes), fumarate hydratase
or fumarase (FH), malate dehydrogenase 2 (MDH2), isocitrate dehydrogenases 1 (cytosolic), 2 and
3 (IDH1/2/3), glutamic-oxaloacetic transaminase 2 (GOT2) and solute carrier family 25 member 11
(SLC25A11) (Figure 1).
Figure 1. Schematic representation of the enzymes and mitochondrial metabolic pathways, tricarboxylic
acid (TCA) cycle, malate/aspartate shuttle, nicotinamide adenine dinucleotide (NADH) exchange
and metabolite efflux from the mitochondria, involved in pheochromocytoma and paraganglioma
(PPGL) development and/or neurodegenerative disorders. Enzymes reported as altered in PPGL
are denoted in red capital letters. Enzymes involved in neurodegenerative disorders are denoted
with an asterisk. SLC25A11: solute carrier family 25 member 11; SLC25A12/SLC25A13: carriers
solute carrier family 25 members 12/13; SLC25A1: solute carrier family 25 member 1; SLC25A19:
solute carrier family 25 member 19; GOT2: mitochondrial glutamic-oxaloacetic transaminase 2; FH:
fumarate hydratase; MDH2: mitochondrial malate dehydrogenase; CS: citrate synthase; ACO2:
mitochondrial aconitase; IDH2: isocitrate dehydrogenase 2; IDH3A/IDH3B/IDH3G: subunits of
isocitrate dehydrogenase 3; L2HGDH: L-2-hydroxyglutarate dehydrogenase; OGDH/DLD/DLST:
subunits of the αKG (alpha-ketoglutarate) dehydrogenase complex; SUCLA2/SUCLG1/SUCLG2:
subunits of succinyl-CoA synthetase; SDHA/B/C/D: subunits of the succinate dehydrogenase
complex; SDHAF1/SDHAF2: succinate dehydrogenase assembly factors; αKG: α-ketoglutarate; TPP:
thiamine pyrophosphate.
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PPGLs are neuroendocrine tumors derived from chromaffin cells of the adrenal medulla and
from neural crest progenitors of extra-adrenal paraganglia. Sympathetic PPGLs, including PCC and
thoracic-abdominal-pelvic (TAP) PGLs, are mostly catecholamine-producing tumors, whereas those
derived from parasympathetic paraganglia, mainly located in the head and neck (H&N) region, are
non-secreting tumors. Although PPGLs are predominantly benign and patients can be cured by
surgical removal of these tumors, they present a significant morbidity and mortality due to the clinical
aggressiveness of metastatic tumors (especially those carrying mutations in TCA cycle-related genes),
for which therapeutic options remain scarce. To note, PPGL is considered a very rare disease with an
incidence of 2–8 patients per million per year (1000–2000 new cases diagnosed worldwide every year).
Therefore, the discovery of new susceptibility genes involved in hereditary predisposition to develop
metastatic PPGLs, which is crucial for genetic counseling, guiding follow-up and developing targeted
therapies, has only been possible through the joint efforts of many groups studying this extremely
rare disease.
3. SDH Genes and PPGL
Germline loss-of-function mutations in SDHA, SDHB, SDHC, SDHD and SDHAF2 (together
accounting for 20% of all PPGLs) cause the well-characterized familial PGL syndromes known as
PGL5 [3], PGL4 [4], PGL3 [5], PGL1 [2] and PGL2 [6], respectively (Table 1). Additional solid tumors
such as gastrointestinal stromal tumors (GISTs) [7], clear cell renal cell carcinomas (ccRCCs) [8] and
pituitary adenomas (PAs) [9] have been associated, albeit rarely, with these familial PGL syndromes [10].
The SDH enzyme complex is a hetero-oligomer that comprises four structural subunits: two
hydrophilic catalytic subunits, SDHA and SDHB, and two hydrophobic subunits that anchor the
catalytic ones to the inner mitochondrial membrane, SDHC and SDHD. The fifth SDH gene associated
with PPGL development, SDHAF2, encodes a cofactor responsible for flavination of SDHA. The SDH
complex catalyzes the oxidative dehydrogenation of succinate to fumarate in the TCA cycle [11], and it
is also functionally involved in the electron transport chain forming the mitochondrial complex II.
Germline or somatic mutations in any of the SDH genes (SDHx) cause disassembly of the mitochondrial
complex, with loss of SDH enzymatic activity and thus triggering the accumulation of its substrate,
succinate. When succinate accumulates pathologically, it acts as a competitor of alpha-ketoglutarate
(αKG) to broadly inhibit the activity of αKG-dependent dioxygenases, such as ten-eleven translocation
(TET) DNA hydroxylases and Jumonji (JMJ) histone lysine demethylases (KDM) [12,13]. This causes
a global hypermethylation with a characteristic CpG island methylation phenotype (CIMP) profile
in the tumors, which leads to altered gene expression and contributes to tumorigenesis; this same
mechanism was earlier observed in glioblastomas [14] and ccRCCs [15] carrying metabolic alterations
such as IDH1/2 and FH/SDHB mutations, respectively. Apart from the aforementioned CIMP profile,
the accumulation of succinate competitively inhibits the family of prolyl hydroxylase domain-containing
proteins (PHD1-3), leading to hypoxia-inducible factor 1 α (HIF-1α) stabilization under normoxic
conditions, and contributing to activation of the pseudohypoxic pathway [16,17]. More recently, it
was reported that the succinate-mediated inhibition of two αKG-dependent dioxygenases, histone
lysine demethylases KDM4A and KDM4B, leads to suppression of homologous recombination [18].
Moreover, the accumulation of succinate also causes downregulation of the enzyme responsible for the
conversion of norepinephrine to epinephrine, thus inducing the characteristic noradrenergic phenotype
of SDHx tumors [13]. All these processes orchestrated by succinate (and fumarate) accumulation (both
referred to as oncometabolites) have been proposed to be involved in tumorigenesis (Figure 2) and/or
in the particular phenotype of PPGLs carrying TCA cycle-related mutations. This will be discussed in
more detail below.
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(% Multiple) BC Related Syndromes; Associated Tumors
SDHD 11q23.1 35y 9–10 (43%, 60y) Low (3–10%) H&N > TAP > PCC M (56%) NA, DA PGL1, Carney-Stratakis syndrome,encephalomyopathy *; ccRCC, GIST, PA
SDHB 1p36.13 30y 10 (13–21%, 50y) High (30–50%) TAP > H&N > PCC S>M (20–25%) NA, DA PGL4, Carney-Stratakis syndrome, hypotoniaand leukodystrophy *; ccRCC, GIST, PA
SDHC 1q23.3 40–50y 1–5 (25%, 60y) Low (<3%) H&N > TAP > PCC S>M (15–20%) NA, DA PGL3, Carney-Stratakis syndrome; GIST, PA
SDHA 5p15.33 40y 3 (10%, 70y) Moderate (12%) H&N > TAP >> PCC S>M (10–15%) NA PGL5, Leigh syndrome *, cardiomyopathy *,leukodystrophy *; ccRCC, GIST, PA
SDHAF2 11q12.2 30–40y 0.1–1 Low H&N >> PCC M (74%) NA PGL2; infantile leukoencephalopathy *
FH 1q42.1 - 1 High (60%) PCC + TAP> H&N M (60%) NA
HLRCC, progressive encephalopathy in early
childhood *; multiple cutaneous and uterine
leiomyomatosis; cutaneous and uterine
leiomyomas, type 2 papillary renal carcinoma
MDH2 7q11.23 45y <1 High (50%) TA S > M (33%) NA Early-onset severe encephalopathy *
IDH1 2q34 >60y NA Low TAP, H&N S NA
SLC25A11 17p13.3 59y 1 High (70%) TAP >> H&N S NA
DLST 14q24.3 29y <1 Low TAP >> PCC M (100%) NA
Chr: chromosome; ¥: penetrance data was included for genes with prevalence >1%; TCA: tricarboxylic acid; PGL: paraganglioma; NA: not applicable; H&N: head and neck paraganglioma;
TAP: thoracic-abdominal-pelvic paraganglioma; PCC: pheochromocytoma; S: single; M: multiple BC: Biochemical predominant secretion; NA: noradrenergic (predominant secretion of
noradrenaline/normetanephrine); A: adrenergic (predominant secretion of adrenaline/metanephrine); DA: dopaminergic (secretion of dopamine/3-methoxytyramine); GIST: gastrointestinal
stromal tumor; ccRCC: clear cell renal cell carcinoma; PA: pituitary adenoma; HLRCC: hereditary leiomyomatosis and renal cell cancer. Other genes found mutated in single cases, such as
GOT2, IDH2 or IDH3B, are not included in the table. *: caused by autosomal-recessive mutations.
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Figure 2. Schematic representation of the consequences of tricarboxylic acid (TCA) cycle disruption in
pheochromocytomas and paragangliomas (PPGL). Upon disruption of the activity of pivotal TCA cycle
enzymes, there is an accumulation of metabolites (i.e., succinate, fumarate, D2HG and L2HG). Their
efflux from the mitochondria to the cytosol and their subsequent competition with α-ketoglutarate
lead to the inhibition of α-ketoglutarate-dependent dioxygenases involved in DNA and histone
demethylation, regulation of HIF, and homologous recombination. As a result, different mechanisms
are proposed as the cause of tumorigenesis in PPGL: aberrant global hypermethylation (CIMP),
activation of the HIF pathway and decreased DNA repair. Finally, different therapeutic options may
target each altered pathway: demethylating agents, HIF inhibitors, and poly-(ADP-ribose)-polymerase
(PARP) inhibitors, respectively. D2HG: D-2-hydroxyglutarate; L2HG: L-2-hydroxyglutarate; TET:
ten-eleven translocation DNA hydroxylase; JMJ: Jumonji; KDM: histone lysine demethylase; PHDs:
prolyl hydroxylase domain-containing proteins; HIF: hypoxia-inducible factor; CIMP: CpG island
methylation phenotype.
3.1. SDHD
Baysal and colleagues described in 2000 the first gene responsible for hereditary PGL [2]. SDHD,
referred to at that time as PGL1 (the gene responsible for hereditary PGL type 1), had been mapped
before to chromosome band 11q23, and was identified by direct sequencing of the best candidate gene
contained in a subsequently narrowed critical interval [19]. The initial link with head and neck (H&N)
PGLs, highly vascular tumors mainly arising in the main sensor of blood oxygenation (the carotid
body), was rapidly extended to PCCs and TAP PGLs [20–22]. Although the original reports proposed
that maternal imprinting accounted for the inheritance pattern observed in SDHD-related pedigrees,
recent studies found that the “almost exclusive” paternal transmission of the disease can be explained
by a somatic genetic mechanism targeting both the SDHD locus and a paternally imprinted gene on
Cancers 2019, 11, 683 6 of 22
11p15.5 [23]. Regardless the mechanism involved, the preferential paternal transmission of the disease
may lead to generation skipping, making genetic counselling challenging. Moreover, though it can
be considered as a rare scenario, development of PPGL may occur after maternal transmission of an
SDHD mutation [24–26]. The estimated risk of PPGL in SDHD mutation carriers (excluding probands)
at age 60 years is 43.2% [11]. Regarding the clinical presentation of SDHD mutations carriers, they
primarily develop (multiple) H&N PGLs (84% of cases), although up to 22% also develop TAP PGLs
and 12–24% develop PCCs (mainly unilateral); 3–10% of carriers develop metastases [27–29]. GISTs,
PAs and, more rarely, ccRCCs can develop in SDHD mutation carriers [30]. It seems that the type of
mutation, either impairing or not SDHD stability, influences the mutation-associated phenotype [27].
3.2. SDHB
One year after the finding of the first SDHD germline mutations in patients with PGL, mutations
in SDHB, the gene encoding the SDH iron-sulfur subunit, were described as the genetic cause of
hereditary PGL type 4 [4]. Soon, the presence of either point mutations or gross deletions affecting
SDHB far surpassed the prevalence of SDHD mutations in patients with PPGL. Overall, mutations
in SDHB and SDHD account for the great majority (over 60%) of all SDHx-related PGL patients,
and SDHB itself accounts for approximately 10% of all PPGLs [31]. Unlike SDHD-associated clinical
manifestations (i.e., multiple H&N PGLs), SDHB mutation carriers are usually diagnosed with single
tumors that can arise in different locations (i.e., PCC, TAP PGL and H&N PGL) [32]. Paradoxically,
mutations in SDHB show one of the lowest penetrances amongst the SDHx genes (13–21% at the age
of 50 years) [11,31,33–35], but patients carrying germline SDHB mutations present a higher risk of
malignancy (~50%) than other SDHx mutation carriers [11,32,36,37]. This latter observation favors the
recommendation of prioritizing genetic testing of this gene in patients affected with PPGL [38]. In fact,
the presence of mutations in SDHB is the best biomarker of poor prognosis and malignancy in PGL
syndromes [36,39]. In addition, the absence of SDHB immunostaining in tumor cells, probably caused
by altered assembly or SDH complex stability, is a reliable identifier of PPGLs caused not only by SDHB
mutations, but also by any other SDHx mutation [40]. Although there is no explanation yet, it has been
reported that male SDHB mutation carriers are at higher risk of disease than females [31]. Amongst the
five SDHx genes, SDHB is the one with the most hereditary extra-paraganglial manifestations, such as
ccRCCs [8,41], oncocytomas [42,43], GISTs [7], and PAs [44].
3.3. SDHC
The SDHC subunit anchors, along with SDHD, the SDH complex to the mitochondrial inner
membrane. Though SDHC was the second SDHx gene identified as a cause of hereditary PGL (PGL
type 3) [5], the frequency of patients carrying mutations in this gene is much lower than SDHB- and
SDHD-related PPGLs, accounting for less than 1% of the patients. SDHC mutations result primarily in
benign and non-functional H&N PGLs, but they have also been identified in patients with sympathetic
PGLs [45,46]. Although no somatic point mutation affecting SDHC has been reported to date in PPGL,
postzygotic epimutations in the gene promoter region have been identified in patients with PGLs [47],
Carney triad (GIST, pulmonary chondroma and PGLs) [48], and Carney-Stratakis syndrome (PGL and
GIST) [49]. This specific molecular mechanism of inactivation of the SDHC gene was first described in
GISTs [50], and has been found in patients developing more than one PGL and/or having syndromic
features resembling a hereditary case, as occurs with endothelial PAS domain protein 1 (EPAS1, also
known as HIF2A) and H3F3A postzygotic somatic mutations. To identify these “genetically hidden”
SDHx cases, a negative immunohistochemistry for SDHB appears to be essential. Although until
now there are few patients reported, it seems that in general SDHC mutation carriers have low risk of
developing GISTs and PAs [11].
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3.4. SDHA
Paradoxically, mutations affecting the gene encoding one of the two major catalytic subunits
of the SDH complex were described subsequently to mutations affecting the other members of the
complex. Homozygous germline mutations of SDHA in patients with Leigh syndrome have been
known since 1995 [51], but the involvement of this gene in the development of PPGL was elusive until
2010 [3]. This can be explained because, although SDHA variants are significantly enriched in PPGL
cases, several SDHA alleles show a high prevalence amongst the normal population (i.e., 0.1–1% in
gnomAD), and were therefore not considered as causative mutations in PPGL patients [52]. Mutations
in SDHA have the lowest penetrance of all major PGL predisposition genes (10% at age 70 years) [53],
and therefore most SDHA mutation carriers will not manifest the disease. Familial PPGL related to
mutations in SDHA shows a prevalence of 3%, especially in patients with PGL, although it is not
rare to find mutations in cases developing PCC [54]. The presence of metastasis in SDHA mutation
carriers is 12%, and extraparaganglial manifestations such as PAs, GIST and ccRCC have also been
described [53–55].
3.5. SDHAF2
Only two different mutations in SDHAF2, encoding one of the known SDH complex assembly
factors, have been described to date in families with H&N PGLs [6,56,57], and one of them
(i.e., p.Gly78Arg) exhibits a founder effect in the Dutch population [58]. As occurs with SDHD
mutation carriers, carriers of SDHAF2 mutations show an exclusively paternal transmission of the
disease, maybe because both genes are located on the same chromosome and may follow the same
route to tumorigenesis [59]. Patients carrying mutations in SDHAF2 develop PGLs only in the H&N
region, and frequently (74% of mutation carriers) in multiple locations [60,61]. Though the SDHAF1
gene has been found mutated in SDH-defective infantile leukoencephalopathy, no mutations have
been reported in PPGL to date [62].
4. Other TCA Cycle-Related Genes
4.1. FH
Fumarate hydratase (FH) catalyzes the reversible hydration of fumarate to malate in the TCA
cycle. Deficiency in FH activity leads to the accumulation of the oncometabolite fumarate and to
the subsequent inhibition of multiple αKG-dependent enzymes, which drives critical epigenetic
changes and signaling pathway activation. Thus, overabundance of fumarate, as occurs with succinate,
leads to stabilization of HIF-1α, deregulation of DNA/histone methylation, increase of glutaminolysis
and glycolysis, and production of reactive oxygen species (something not found in SDH-mutant
PPGLs) [63]. All these altered phenomena could promote carcinogenesis by stimulating proliferation
and cell survival. Inactivating germline mutations affecting the FH gene are the cause of hereditary
leiomyomatosis and renal cell carcinoma (HLRCC) [64], but, as far as we know, no PPGL has been
reported in families with HLRCC. In 2013, a germline mutation in FH was found in a patient with PCC by
whole exome sequencing (WES) applied to a tumor displaying transcriptional and methylation (CIMP
profile) similarities to SDH-mutant tumors [13]. Subsequently, the study of two large series of patients
allowed the identification of additional patients carrying inactivating germline FH mutations [65,66].
The prevalence of alterations in the gene is about 1% in PPGL patients, and a metastatic phenotype
and presence of multiple tumors located in the adrenal gland or in TAP paraganglia are the clinical
characteristics of PPGLs associated with FH mutations. In addition, fumarate causes a non-enzymatic
covalent modification of cysteine residues in proteins, S-(2-succinyl) cysteine (2SC) [67], that can be
detected by immunohistochemistry and has been proposed as a biomarker for FH-associated neoplasia.
This protein modification, called succination, is different from succinylation, another post-translational
modification that will be discussed later in this review. The extent of succination and the implications
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it may have for the function of targeted proteins is poorly studied, but it seems that this process is
more likely to lead to inactivation of critical enzymes [68,69].
4.2. MDH2
MDH2 encodes the enzyme malate dehydrogenase 2, which is essential for the reversible oxidation
of malate to oxaloacetate in the TCA cycle. This tumor suppressor gene was first reported mutated,
with an incomplete penetrance, in a single family with multiple malignant PGLs [70]. Very recently,
additional variants have been reported, accounting for <1% of the patients, and their involvement
in noradrenergic PPGLs with malignant behavior has been suggested [71]. Tumors carrying MDH2
mutations showed no accumulation of malate, and though knockdown of MDH2 in HeLa cells triggered
the accumulation of both malate and fumarate, the connection between mutations in this gene and
tumorigenesis is not clear. Subsequent to the finding of MDH2 mutations in PPGL, biallelic mutations
of the gene were found as the cause of severe encephalopathy in pediatric patients [72], reinforcing the
pathological role of alterations in this particular gene.
4.3. IDH Genes
Isocitrate dehydrogenases IDH1 (cytoplasmic) and IDH2 (mitochondrial) catalyze the oxidative
decarboxylation of isocitrate to αKG. Recurrent, and mutually exclusive, mutations in the genes IDH1
(involving R132) and IDH2 (involving R172), result in neomorphic production of the oncometabolite
D-2-hydroxyglutarate (D2HG) that ultimately causes the characteristic CIMP profile previously
mentioned for succinate and fumarate accumulation [73]. Somatic mutations in the IDH1 gene
(p.R132C), frequently found in central nervous system tumors [74], have been rarely identified in
PGLs (i.e., three benign tumors in TAP or H&N locations) [49,75,76]. On the other hand, only one
somatic IDH2 mutation has been found in a patient with a single H&N PGL by metabolome-guided
genomic analysis [77]. Moreover, we recently found a germline truncating mutation affecting IDH3B
in a patient with a single H&N PGL showing an altered αKG/isocitrate ratio and a CIMP-like
profile [49]. Homozygous loss-of-function mutations in IDH3B have been found in families with
retinitis pigmentosa, a hereditary neurodegeneration of rod and cone photoreceptors in the retina [78].
IDH3 is a heterotetramer, with two catalytic subunits encoded by IDH3A and two regulatory subunits
encoded by IDH3B and IDH3G, which catalyzes the irreversible conversion of isocitrate to αKG in
the TCA cycle. Although the finding of an IDH3B loss-of-function variant in a neuroendocrine tumor
such as PGL suggests a causative role for this gene in the disease, and also for the other two genes
encoding the remaining subunits of the tetramer, further studies are needed to definitively confirm
this association.
4.4. SLC25A11 and GOT2
Another WES study applied to a tumor exhibiting an SDHx-like molecular phenotype
(i.e., pseudohypoxic and CIMP profiles) in the absence of SDHx or FH mutations, identified a
germline mutation in the SLC25A11 gene, which encodes the mitochondrial α-KG/malate carrier [79].
Five additional patients, most of them developing metastatic TAP PGLs, were found in this study
carrying SLC25A11 mutations. This gene is not directly involved in the TCA cycle, but it participates in
the exchange between two major intermediates of the cycle, which suggests that inactivation of other
genes causing alterations in mitochondrial homeostasis can be responsible for PPGL development
as well. Moreover, a single gain-of-function mutation in the GOT2 gene, encoding the mitochondrial
glutamic-oxaloacetic transaminase and also involved in stimulating the malate/aspartate shuttle, was
recently reported in a patient with multiple metastatic PGL [49], further reinforcing the link between
dysfunction of proteins involved in the exchange of metabolites between the mitochondria and the
cytoplasm and PPGL.
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4.5. New TCA Cycle-Related Genes Involved in PPGL Development
Recently, a recurrent germline variant affecting DLST was found in PPGL patients with multiple
tumors [80]. DLST (dihydrolipoamide S-succinyltransferase) is one of the three components (the E2
component) of the 2-oxoglutarate dehydrogenase (OGDH) complex that catalyzes the overall conversion
of αKG to succinyl-CoA and CO2. Accumulation of L-2-hydroxyglutarate (L2HG) was found both
in DLST-mutated tumors and in DLST-knockout (KO) cells transfected with the mutated protein.
Surprisingly, and despite the mentioned accumulation, DLST-mutated tumors did not exhibit a
CIMP profile, but they showed methylation and expression profiles similar to those observed for
EPAS1-mutated PPGLs, suggesting a link between DLST disruption and pseudohypoxia. Moreover,
a high HIF3A expression and a positive DLST immunostaining exclusively found in tumors carrying
TCA cycle mutations or EPAS1 mutations further supported this pseudohypoxic link.
5. Metabolic Remodeling not Associated with TCA-Cycle Alterations
Apart from the mentioned TCA cycle alterations, metabolic reprograming of cancer cells can be
achieved in PPGLs by other molecular mechanisms. Mutations in EPAS1, as well as the stabilization of
HIF-1α occurring in VHL- and PHD-mutated PPGLs, trigger a pseudohypoxic switch of metabolism
from mitochondrial respiration to glycolysis irrespective of oxygen levels. On the other hand, MYC
deregulation caused by mutations in MAX may increase, in cooperation with HIF-2α, glucose uptake
and glycolysis. Moreover, activating alterations of the phosphatidylinositol 3-kinase (PI3K)/AKT
serine-threonine kinase (Akt)/mammalian target of rapamycin (mTOR) pathway (by loss-of-function
mutations in NF1 and TMEM127, or gain-of-function mutations in RET, FGFR1 and HRAS) can also
increase glycolysis through the transcription of glycolytic enzymes [63].
6. Inborn TCA Cycle Alterations: Neurodegenerative Disorders versus Cancer
The relevance of hereditary alterations in TCA cycle-related genes to the etiology of severe
mitochondrial disorders is well known. Thus, autosomal-recessive mutations in almost any of the
genes encoding the main enzymes of the TCA cycle lead to different forms of encephalopathies (Figure 1).
This is the case for recessive germline mutations in SUCLG1 [81] and SUCLA2 [82]. Moreover, ACO2
alterations cause infantile cerebellar-retinal degeneration [83] and severe optic atrophy and spastic
paraplegia [84]; IDH3A mutations lead to severe encephalopathy in infancy [85]; mutations in DLD cause
severe encephalopathy and hyperlactatemia with neonatal onset [86]; homozygous IDH2 mutations
provoke developmental delay, epilepsy, hypotonia, cardiomyopathy, and dysmorphic features [87];
SDHAF1 mutations lead to infantile leukoencephalopathy [62]; SDHA alteration is a well-known
cause of Leigh syndrome, cardiomyopathy and leukodystrophy [51]; recessive SDHB mutations lead
to hypotonia and leukodystrophy [88] and SDHD mutations cause encephalomyopathy [89]; FH
alterations cause progressive encephalopathy in early childhood [90]; and MDH2 mutations provoke
early-onset severe encephalopathy [72]. In addition, homozygous mutations in SLC25A1, encoding a
mitochondrial citrate carrier, cause combined D-2- and L-2-hydroxyglutaric aciduria, severe neonatal
epileptic encephalopathy, absence of developmental progress, and often early death [91], and mutations
in SLC25A19, encoding a mitochondrial transporter of a TCA cycle cofactor (thiamine pyrophosphate),
cause encephalopathy and progressive polyneuropathy [92]. Finally, L2HGDH alterations cause
macrocephaly, developmental delay, epilepsy, and cerebellar ataxia [93].
Considering that complete abrogation of the TCA cycle in cells is highly unlikely to be compatible
with cell viability, how is it possible that homozygous germline mutations in TCA cycle-related
genes exist? The first mammalian model lacking a protein of the TCA cycle was obtained in 1997.
Johnson et al. generated viable DLD+/− mice, while the homozygous knockout animals (DLD−/−) died
at early embryonic stages [94]. This also occurred with SDHD [95], FH [96], DLST [97], SDHB [13] and
SUCLA2/SUCLG2 [98] knockout mice. Overall, these data suggest that complete lack of activity of
TCA cycle enzymes appears to be deleterious during embryonic development. These observations
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imply that homozygous or compound heterozygous variants in TCA cycle-related genes associated
with neurological disorders do not completely abolish the corresponding enzymatic activity and retain
part of their functionality. However, the presence of homozygous or compound heterozygous SDHx
mutations in patients with neurological disorders gives rise to a controversial situation, which is
the absence of tumors in mutation carriers. In heterozygous mutation carriers, this can be either
accounted for by the low penetrance of TCA cycle-related mutations (especially in the case of
SDHA and SDHB variants) or by the aforementioned modest effect of the alterations found in these
patients. In addition, though clinical presentation and survival may be variable [99], patients carrying
homozygous or compound heterozygous germline mutations in TCA cycle genes are usually diagnosed
at a young age and die within a few years of diagnosis before reaching adulthood [100], so tumor
diagnosis is unlikely to occur in these patients. However, taking into account that patients with
L-2-hydroxyglutaric aciduria show increased risk of brain tumors [101], the tumorigenic potential of
recessive mutations in TCA cycle-related genes cannot be ruled out. Both PPGL patients carrying TCA
cycle-related mutations and patients with encephalopathies associated with the presence of recessive
mutations in the aforementioned genes may benefit from therapeutic approaches targeting the aberrant
DNA/histone methylation and the DNA-repair pathway, such as the use of demethylating agents
(5-aza-2′-deoxycytidine or decitabine, for instance) or PARP inhibitors, respectively.
7. TCA Cycle-Related Omics Profiling in PPGLs
7.1. Pseudohypoxic Transcriptional Profile
The major regulator of cellular response to limited levels of oxygen (hypoxia) is the heterodimeric
(composed of alpha and beta subunits) basic helix-loop-helix transcription factor HIF-1α. Under low
oxygen conditions, HIF-1α (and also HIF-2α) activates the transcription of many genes involved in
the metabolic adaptation to hypoxia, including transporters for increased glucose import (favoring
anaerobic growth by glycolysis) and genes encoding angiogenesis factors [102]. The regulation of
HIF-1α activity involves oxygen-limited hydroxylation of prolyl residues carried out by PHD1-3 prolyl
hydroxylases. This prolyl hydroxylation induces the binding of HIF-1α to the von Hippel–Lindau
(VHL) protein-associated complex, which is in charge of targeting HIF-1α by ubiquitination for
proteosomal degradation [103,104]. Prolyl hydroxylation of HIF-1α requires oxygen, iron, and αKG,
and the reaction produces succinate. Under hypoxia, prolyl hydroxylation is inhibited, HIF-1α is
not ubiquitinated and this leads to the transcription of HIF-responsive genes. However, cancer cells
may reproduce the hypoxic gene expression signature regardless of the oxygen condition in a process
known as pseudohypoxia. This process is the hallmark of the VHL syndrome, in which mutations of
VHL lead to HIF-1α stabilization in normoxia, leading to the development of tumors (e.g., ccRCCs
and PPGLs). The pseudohypoxic transcriptional profile associated with the presence of mutations in
TCA cycle-related genes in PPGL was first described by Patricia L Dahia in 2005. In this pioneering
study, it was shown that SDH mutations, and the subsequent accumulation of succinate, caused a
pseudohypoxic transcription profile similar to the one originated by VHL dysfunction [16,63,105].
Chronic pseudohypoxic signaling could be a mitogenic tumor initiator in neuroendocrine cells,
and therefore inappropriate HIF-1α or HIF-2α persistence due to loss of SDH function in PPGL
could drive tumorigenesis [106,107]. To note, the only environmental risk factor described in PPGL is
chronic hypoxia which, in populations living at high altitude, leads to an increased incidence of H&N
PGLs [108–111]. However, though the accumulation of oncometabolites is undoubtedly linked to
tumor development in PPGLs, the subsequent pseudohypoxic response is not the only downstream
mechanism proposed to explain tumorigenesis caused by TCA cycle dysfunction. The identification
and validation of HIF-2α as one of the main oncogenic drivers in PPGLs [112–114] provides a
rationale for exploring direct inhibition of HIF-2α as a therapeutic target in metastatic patients [115].
Preclinical studies have shown that HIF-2α antagonists are capable of inhibiting tumor growth
in several models of renal cancer, and clinical trials of the first-in-class HIF-2α antagonist PT2385
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[(S)-3-((2,2-difluoro-1-hydroxy-7-(methylsulfonyl)-2,3-dihydro-1H-inden-4-yl)oxy)-5-fluorobenzonitrile]
have achieved promising results in ccRCC [116]. These findings set the stage for future trials focused
on metastatic PPGL, a tumor type that, similar to ccRCC, harbors the pseudo-hypoxia molecular
signature as its main molecular hallmark [117,118].
7.2. TCA-Cycle Mutations and CpG Island Methylator Phenotype (CIMP)
The association between the presence of SDHx mutations and CIMP in PPGL has been known
since 2008 [119]. Geli et al. performed a quantitative evaluation of promoter methylation of a set of
tumor suppressor genes (i.e., RASSF1A, RASSF5, CDKN2A, RARB, TNFRSF10D, CDH1, and APC),
and found that five of seven tumors exhibiting a targeted CIMP profile were mutated in SDHB.
Moreover, this particular CIMP profile (defined by the presence of methylation in at least three of the
genes included in the analysis) was associated with metastatic behavior and extra-adrenal location
(both clinical characteristics related to SDHx mutations). Later, it was published that the accumulation
of fumarate and succinate, upon FH or SDHx mutations respectively, led to enzymatic inhibition of
multiple α-KG-dependent dioxygenases and consequent alterations of genome-wide histone and DNA
methylation, linking the TCA cycle mutations to tumorigenesis by their effect on the epigenome [12].
Interestingly, and like a snake that bites its tail, the methylation of the promoter of SDHC is a very
well-known mechanism leading to CIMP in GIST [50] and PPGLs [47,49]. In 2013, two separate
studies based on DNA methylation profiling of samples carrying SDHx mutations further explored
the connection between metabolic disruption and altered epigenetic modifications [13,120]. These
studies uncovered that SDH deficiency, and the subsequent accumulation of succinate, led to DNA
hypermethylation in multiple tumor lineages (e.g., PPGLs and GISTs). These epigenomic changes were
particularly severe in SDHB-mutated tumors, potentially explaining their malignancy. To note, one of
these methylation-based studies also uncovered mutations in FH as a cause of hereditary PPGL [13],
expanding the CIMP to another TCA cycle-related gene beyond the SDHx genes. In addition, a sporadic
PPGL has been also described showing CIMP associated with the presence of a IDH1 mutation [49] but,
as previously mentioned, tumors carrying DLST mutations do not exhibit the characteristic CIMP profile
despite their accumulation of TCA metabolites [80]. To date, the presence of mutations in other genes
involved in the epigenetic machinery in PPGLs exhibiting hypermethylation [121,122], and the finding
of tumors with a CIMP profile not associated with mutations in any TCA cycle-related gene [49], further
suggest that other genes and pathways may be involved in this particular phenotype. Additional
studies are required to elucidate whether the accumulation of metabolites, and the subsequent CIMP,
is the cause or a consequence of the tumorigenic process and the adverse outcome associated with
some TCA cycle mutations in PPGL.
7.3. Metabolome-Guided Genetic Characterization of the TCA Cycle
Since a link between pathological accumulation of TCA cycle metabolites and tumorigenesis was
established, the study of the PPGL-associated metabolome has been used in the characterization of
tumors carrying common genetic alterations, and additionally, in the identification of new candidate
genes [49], the interpretation of genetic variants, and the improvement of diagnostics [77,123,124].
Mass spectrometry-based measurements of succinate:fumarate ratios allow to distinguish between
SDH-deficient PPGLs and tumors without dysfunction of the SDH complex [123]. This is true, except
in the case of some H&N PGLs, which may exhibit higher fumarate levels and therefore lower
succinate:fumarate ratios compared to those at adrenal or TAP locations. The absence of this particular
metabolic signature in some H&N PGLs is probably due to their higher content of stromal cells that
dilute the signal from the tumor cells. In addition, alterations in the metabolites’ ratios can be used to
identify hidden alterations in other TCA cycle-related genes. Thus, a tumor with a gain-of-function
GOT2 mutation exhibited a high succinate:fumarate ratio, probably due to the accumulation of αKG
and its subsequent conversion to succinate [49]. Moreover, high fumarate:malate ratios have been
observed in PPGLs carrying FH mutations, high absolute values of D2HG can be detected in PPGLs
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carrying IDH1/2 mutations [49,77], and accumulation of L2HG was found both in DLST-mutated
PPGLs and in DLST-KO cells transfected with the mutated protein [80].
In addition, hypermethylation (and the subsequent downregulation) of genes involved in the
biosynthesis (PNMT, DRD2 and SULT1A1), transport (SLC6A2), and secretion (NPY) of catecholamines
found in SDH- and FH-mutant PPGLs [13], may contribute to the immature catecholamine phenotypic
features of PGLs carrying mutations in TCA cycle-related genes [124]. Thus, the reduced PNMT
expression reported in SDH-mutant tumors has been proposed to cause the predominant secretion of
noradrenaline or dopamine observed in these tumors.
8. Link Between Defective TCA Cycle and DNA Repair
On the whole, mutations affecting TCA cycle-related genes are associated with metastatic PPGLs
for which curative chances, if any, are very limited. For that reason, the recently reported link between
accumulation of TCA cycle oncometabolites and homologous recombination paves the way for new
therapeutic approaches to the treatment of metastatic PPGL. Moreover, FH enzymatic activity is
required for the cellular DNA damage response to double-strand breaks, and it is known that it is
involved in the non-homologous end joining repair pathway [125,126]. Thus, in this unexpected
connection between metabolism and DNA repair, the excess of fumarate and succinate not only
would inhibit αKG-dependent dioxygenase activities, specifically the lysine demethylases KDM4A
and KDM4B, but also would suppress the homologous recombination pathway [18]. This blockage
would avoid the maintenance of genomic integrity and would make cells vulnerable to synthetic-lethal
targeting with poly [adenosine diphosphate (ADP)]-ribose polymerase (PARP) inhibitors. Recent
findings have revealed that the expression of mitochondrial complex I core subunits were upregulated
in PPGLs with a pseudohypoxic profile. This augmented complex I activity increases intracellular
nicotinamide adenine dinucleotide (NAD+) levels, which serves as an important cofactor to support
the PARP DNA repair pathway. Thus, pseudohypoxic PPGLs would present more efficient DNA repair,
resulting in potential chemoresistance.Interestingly, a combined treatment with a PARP inhibitor and
temozolomide improved cytotoxicity in vitro, reducing tumor proliferation and metastatic lesions with
prolonged overall survival in mice with SDHB-KO allografts [127].
9. Defective TCA Cycle Metabolism, Succinylation of Histones and Transcriptional Responses
In addition to the mentioned effects that the accumulation of TCA cycle metabolites has on
overall DNA methylation, there are other less known implications of disruption of the cycle. Lysine
succinylation is a known post-translational protein modification [128] that when occurring in histones
may affect chromosome structure and function [129]. It was recently demonstrated that a fraction of
the OGDH complex localizes in the nucleus and binds to lysine acetyltransferase 2A (KAT2A) in the
promoter regions of genes [130], and this nuclear translocation of the complex depends on a nuclear
localization sequence in DLST. Preventing the OGDH complex from entering the nucleus avoids
nuclear generation of succinyl-CoA and the subsequent KAT2A-dependent H3 succinylation, reducing
gene expression and inhibiting tumor cell proliferation and tumor growth. These results are consistent
with previous observations linking nucleosome succinylation with enhanced in vitro transcription.
These interesting findings not only might explain the tumorigenic potential of DLST, as part of the
OGDH complex, but also open a new avenue of research into the connection of metabolism and cancer.
A subsequent study also demonstrated a potential role of chromatin succinylation in modulating
gene expression using an inducible cell culture model of SDH loss, which results in accumulation of
succinyl-CoA [131]. This study also demonstrated that defective TCA cycle metabolism results in a
DNA repair defect. Chromatin succinylation may thus represent a mechanism by which metabolism
modulates both genome-wide transcription and DNA repair activities.
Apart from the aforementioned effect on the succinylation of histones, inhibition of the OGDH
complex also reduces lysine succinylation of cytosolic and mitochondrial proteins altering rates of
enzymes and pathways, especially mitochondrial metabolic pathways [132,133]. Moreover, ablation of
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specific enzymes of the TCA cycle affects the availability of succinyl CoA and global enzymatic and
non-enzymatic succinylation patterns [134], providing a novel mechanism in which mitochondrial
intermediates act as sensors to regulate metabolism.
10. Can We Open New Therapeutic Avenues for TCA Cycle-Altered PPGLs?
Apart from the known approaches to treating malignant PPGLs [135,136], we will discuss here
novel therapeutic strategies that should be pursued for tumors carrying alterations in the TCA
cycle. Though overall PPGLs present a low degree of chromosome instability, about 2–3% of tumors
show chromothripsis involving chromosome arm 1p, where SDHB is located [129]. Chromothripsis
phenomenon is a form of genome instability, associated with poor prognosis [137,138], in which one or
a few chromosomes are affected by an alternating copy number profile with both loss and retention
of heterozygosity [139,140]. One of the mechanisms involved in the initiation of chromothripsis is
telomere dysfunction that leads to attrition of chromosome ends [141]. Subsequently, cancer cells
showing this phenomenon become stabilized in order to avoid additional chromosomal aberrations
that would be incompatible with cell survival. A well-known telomere stabilization mechanism
involves the presence of high levels of TERT mRNA, mainly through amplification, promoter point
mutations, methylation or rearrangements. Interestingly, increased TERT expression and telomere
length has been observed in chromothripsis-positive ependymomas and glioblastomas [142], and in
high-stage neuroblastomas [143] among other cancers, suggesting that telomere maintenance pathways
may represent therapeutic targets in chromothripsis-positive tumors. With regard to PPGL, high
to moderate TERT expression has been observed in 18–51% of patients, which are often metastatic
cases [75,144,145], and in an important proportion of patients associated with deficiency of SDHx [146].
Moreover, the presence of somatic ATRX mutations, found preferentially in SDHB/FH-mutated tumors,
and the associated alternative lengthening of telomeres have been described as an independent risk
factor for metastatic PPGL [75,146,147]. It is tempting to speculate that metastatic PPGLs related to
mutations in other TCA cycle genes that also exhibit telomere dysfunction, could benefit from the
multiple telomerase-targeting therapeutic strategies that have been pursued in the past two decades
(reviewed in [148]).
Another important avenue of potential treatments for metastatic PPGLs focuses on investigating
whether a specific driver mutation could be associated with the tumor’s immune profile, and therefore
with the potential efficacy of immunotherapy. In this regard, one of the main problems related to the
potential lack of response is immune evasion, in which the tumor microenvironment (TME) plays a
pivotal role [149]. The TME can be influenced by different conditions, but there are two in particular
that gain importance when considering PPGLs with TCA-mutated genes: the hypoxic state, and an
aberrant production of metabolites. Whether the PPGL immune subtypes are genotype-specific, or
if there is an enrichment of any immune subtype among SDHB-mutated tumors or among those
related to TCA genes with a higher metastatic risk is still to be addressed. Regardless these upcoming
knowledge, it seems clear that a highly heterogeneous disease such as PPGL will benefit from a
personalize treatment based on the specific genetic background, as well as from a deep characterization
of the tumor microenvironment.
11. Conclusions
More than 20% of PPGLs are found carrying mutations in genes encoding TCA cycle metabolic
enzymes. These mutations cause the disruption of the cycle, and the subsequent accumulation of
“oncometabolites” lead to overall pathological changes in gene expression (i.e., by DNA methylation
and post-translational protein modification), metabolic adaptation of cells to hypoxia, and DNA repair
processes. Unraveling the pathological mechanisms associated with the presence of different PPGL
mutations could pave the way to new personalized therapeutic approaches.
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